Montefiore Medical Center

Researchers

• MKMarina Konopleva

Running trials

• Not yet recruiting

  Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease

  NCT06510296· Montefiore Medical Center· Source

• Recruiting

  Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

  NCT07615049· Phase 3· SWOG Cancer Research Network· Source

• Recruiting

  A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  NCT07310420· Phase 1· TerSera Therapeutics LLC· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.

  NCT07920484· Amber Implants B.V.· Source

• Not yet recruiting

  A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

  NCT06458907· P+F Products + Features USA Inc.· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Not yet recruiting

  The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

  NCT07146230· Phase 2· Montefiore Medical Center· Source

• Recruiting

  A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation

  NCT07527299· Biosense Webster, Inc.· Source

• Recruiting

  Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  NCT07022678· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

  NCT07421167· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  NCT07441681· Phase 3· NRG Oncology· Source

• Recruiting

  Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department

  NCT07228052· Phase 4· Montefiore Medical Center· Source

• Recruiting

  Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

  NCT07452458· Phase 3· NRG Oncology· Source

• Recruiting

  Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

  NCT07725380· Phase 1/2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Children's Oncology Group· Source

• Recruiting

  ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

  NCT07559903· Emory University· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· AbbVie· Source

• Recruiting

  Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

  NCT07671911· Phase 3· Trevi Therapeutics· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Quetzal Therapeutics· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

  NCT07563881· Phase 3· Rapport Therapeutics Inc.· Source

• Recruiting

  Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

  NCT07290140· Airiver Medical, Inc.· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

  NCT07296744· Supira Medical· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

  NCT07523750· Biosense Webster, Inc.· Source

• Recruiting

  Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Impact of Barostimulation on Hemodynamics in Adults With Heart Failure

  NCT07335510· Columbia University· Source

• Recruiting

  Continuous Dual Aspiration Technique With Zoom System for Stroke

  NCT07491952· Imperative Care, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· NRG Oncology· Source

• Recruiting

  Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  NCT07194044· Phase 1· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

  NCT07283094· Phase 1· Montefiore Medical Center· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Phase 1· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  Digoxin Medulloblastoma Study

  NCT06701812· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Not yet recruiting

  The ORCHESTRATE-Myocarditis Registry

  NCT05139329· Kansas City Heart Rhythm Research Foundation· Source

• Recruiting

  Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  NCT07104565· Phase 2· Incyte Corporation· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  NCT06686771· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Pfizer· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis

  NCT07116551· Abbott Medical Devices· Source

• Recruiting

  A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

  NCT07227532· Biosense Webster, Inc.· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

Showing 50 of 454.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers37 recruiting
• Lung cancer21 recruiting
• Acute myeloid leukaemia18 recruiting
• Prostate cancer12 recruiting
• Sarcoma12 recruiting
• Head and neck cancer9 recruiting
• Myelodysplastic syndromes9 recruiting
• Stroke9 recruiting
• Coronary artery disease8 recruiting
• Acute lymphoblastic leukaemia7 recruiting
• Atrial fibrillation7 recruiting
• Heart failure6 recruiting
• Aortic stenosis5 recruiting
• Brain aneurysm5 recruiting
• Metastatic breast cancer5 recruiting
• Myeloproliferative neoplasms5 recruiting
• Bladder cancer4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Colorectal cancer4 recruiting
• HIV4 recruiting
• Immune thrombocytopenia (ITP)4 recruiting
• Ovarian cancer4 recruiting
• Asthma3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Down syndrome3 recruiting
• Follicular lymphoma3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Kidney cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Multiple myeloma3 recruiting
• Sickle cell disease3 recruiting
• Triple-negative breast cancer3 recruiting
• Chronic kidney disease2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Crohn's disease2 recruiting
• Endometrial cancer2 recruiting
• Epilepsy2 recruiting
• Glioblastoma2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Migraine2 recruiting
• Neuroblastoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Osteoporosis2 recruiting
• Pancreatic cancer2 recruiting
• Ulcerative colitis2 recruiting
• Alopecia areata1 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Brain metastases1 recruiting
• Burkitt lymphoma1 recruiting
• Cervical cancer1 recruiting
• Chronic rhinosinusitis with nasal polyps1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Dystonia1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Mild cognitive impairment1 recruiting
• Myocarditis1 recruiting
• Nephrotic syndrome1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sarcoidosis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thalassaemia1 recruiting
• Trigeminal neuralgia1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Terminated

  Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

  NCT06775886· Montefiore Medical Center· Source

• Completed

  Data Collection for Echocardiography-Based Software Assessment

  NCT07126600· Anumana, Inc.· Source

• Completed

  Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

  NCT06604442· Phase 4· Blue Earth Diagnostics· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  A Postpartum Adaptation Study of the Connecting and Reflecting Experience Parenting Program

  NCT06042166· Montefiore Medical Center· Source

• Terminated

  A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Phase 1/2· Sanofi· Source

• Completed

  Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology

  NCT05968924· Montefiore Medical Center· Source

• Completed

  PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

  NCT06366451· Early phase 1· Presage Biosciences· Source

• Completed

  Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

  NCT06331624· Phase 2· GRI Bio Operations, Inc.· Source

• Completed

  RECOVER-AUTONOMIC Platform Protocol

  NCT06305780· Phase 2· Kanecia Obie Zimmerman· Source

• Withdrawn

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  NCT06064877· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Biosense Webster, Inc.· Source

• Completed

  The PEERLESS II Study

  NCT06055920· Inari Medical· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  HEAL-LAA Clinical Trial

  NCT05809596· Boston Scientific Corporation· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Ferring Pharmaceuticals· Source

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· United Therapeutics· Source

• Completed

  Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

  NCT05510908· AIDS Malignancy Consortium· Source

• Completed

  Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

  NCT05775406· Phase 1· Kymera Therapeutics, Inc.· Source

• Completed

  Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

  NCT05630001· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  Sphenopalatine Ganglion Block Study

  NCT05707754· Phase 1· Montefiore Medical Center· Source

• Completed

  NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

  NCT05666713· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Completed

  Hospital Airway Resuscitation Trial

  NCT05520762· Montefiore Medical Center· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Terminated

  Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

  NCT05682170· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Multicultural Healthy Diet in Chronic Kidney Disease

  NCT05504850· Montefiore Medical Center· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Pfizer· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Escient Pharmaceuticals, Inc· Source

• Terminated

  Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization

  NCT05118204· Phase 4· Montefiore Medical Center· Source

• Completed

  Testing Two Models of PrEP Delivery in OBGYN Clinics

  NCT05015855· Montefiore Medical Center· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· H. Lundbeck A/S· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· Phase 1· Cue Biopharma· Source

• Completed

  A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

  NCT05368285· Phase 2· Celldex Therapeutics· Source

• Completed

  IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

  NCT05077709· Phase 2· IO Biotech· Source

• Terminated

  A Study to Investigate LYL797 in Adults With Solid Tumors

  NCT05274451· Phase 1· Lyell Immunopharma, Inc.· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Pfizer· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Completed

  Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

  NCT04600336· Phase 2· Alliance for Clinical Trials in Oncology· Source

Showing 50 of 173.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke138 works · 18 trials
• Heart failure122 works · 19 trials
• Atrial fibrillation71 works · 20 trials
• Coronary artery disease43 works · 17 trials
• Migraine30 works · 9 trials
• Aortic stenosis29 works · 9 trials
• Acute myeloid leukaemia23 works · 35 trials
• Endometrial cancer15 works · 12 trials
• Sickle cell disease10 works · 11 trials
• Brain aneurysm10 works · 10 trials
• Hidradenitis suppurativa9 works · 2 trials
• Myelodysplastic syndromes8 works · 16 trials
• Hydrocephalus8 works · 3 trials
• Ventricular tachycardia8 works · 1 trial
• Haemophagocytic lymphohistiocytosis4 works · 0 trials
• Cushing's syndrome3 works · 0 trials
• Narcolepsy3 works · 0 trials